How Did Insulin Evolve from a Laboratory Extract to Modern Life-Saving Therapy?
Step by step, with each advance fixing a practical problem. Crude dog pancreas extracts lowered blood sugar in 1921. The first human injection came in January 1922. Purified animal insulin followed within a year, longer-acting protamine and zinc insulins arrived in the 1930s, recombinant human insulin reached the market in 1982, and engineered analogs began with lispro in 1996. The larger story starts in 1889, when removing a dog’s pancreas was shown to cause diabetes. It ends, unfortunately, with a modern pricing crisis that has put this life-saving medication out of reach for many who need it most.
Dr. Kumar’s Take
Insulin’s history represents both the best and worst of medical progress. The scientific journey from understanding diabetes to developing life-saving therapy showcases human ingenuity and collaboration at its finest. However, the transformation of insulin from an affordable medication into a luxury commodity represents a betrayal of the discoverers’ vision and a failure of the U.S. healthcare system. Understanding this complete history makes it easier to appreciate both the remarkable scientific achievement and the urgent need to restore insulin’s accessibility.
Key Findings
- 1921: Frederick Banting and Charles Best began experiments in John Macleod’s Toronto lab on May 17. By September, their pancreatic extract lowered blood sugar in dogs with diabetes. Biochemist J.B. Collip then helped purify it for human use.
- January 11, 1922: The first injection, given to a 14-year-old boy, caused a sterile abscess and only a mild drop in blood sugar. Collip’s purified extract worked later that year: blood sugar fell and ketones disappeared from the urine.
- 1923: The Nobel Prize followed. Eli Lilly began making insulin from animal pancreas, but potency varied by up to 25% between lots. A new purification method cut that variation to 10%. In Denmark, the non-profit Nordisk Insulin Laboratory began production.
- 1930s: Hans Christian Hagedorn prolonged insulin’s action by adding protamine, and Scott and Fisher in Toronto added zinc. Protamine zinc insulin lasted 24 to 36 hours. NPH (neutral protamine Hagedorn) lasted about 24 hours and could be mixed with regular insulin.
- 1978 to 1982: Genentech made the first recombinant DNA human insulin in 1978. Lilly marketed it as Humulin R and N in 1982.
- 1993: The Diabetes Control and Complications Trial showed that tighter glucose control means fewer long-term complications.
- 1996 to 2005: Analogs designed to mimic the body’s own mealtime and background insulin arrived: lispro (1996), aspart (2000) and glulisine (2004) for meals, and glargine (2000) and detemir (2005) as basal insulins.
- 2006: Exubera, the first inhaled insulin, reached the market. It offered no advantage over rapid-acting analogs and was withdrawn after two years.
Separately, U.S. list prices for insulin rose steeply in the 2000s and 2010s, mostly for patented analogs, so that as insulin became more sophisticated, it also became less accessible to many patients.
Brief Summary
This short 2012 review by Quianzon and Cheikh traces diabetes treatment from the Ebers papyrus of ancient Egypt, through the fasting diets that were the only option before insulin, to Banting and Best’s 1921 discovery, the purification and lengthening of animal insulin, recombinant human insulin, insulin analogs, and inhaled insulin. It shows how insulin changed from a crude pancreatic extract into precisely engineered proteins. The earlier 1889 work of von Mering and Minkowski, who showed that removing the pancreas causes diabetes, and the later rise in insulin prices are part of the wider history covered in this article.
Study Design
This is a brief narrative review with 19 references, drawn from published histories, clinical trial reports, and FDA drug records. It is a summary of the historical record, not a systematic analysis.
Results You Can Use
Each major step in insulin’s history solved a practical problem. Purification cut lot-to-lot potency swings from up to 25% to 10%. Protamine and zinc stretched a dose to a day or more, so people needed fewer injections. Recombinant DNA ended the reliance on animal pancreas. Analogs were built to reduce low blood sugar, which the review calls the main limit on tight glucose control.
On cost, the wider record is different. The early Toronto team and Nordisk treated insulin as a public health necessity. U.S. list prices rose steeply in the 2000s and 2010s, mostly for patented analogs, at a time of modest therapeutic change. Older human insulins such as regular and NPH remain effective and usually cost less.
Why This Matters For Health And Performance
Understanding insulin’s complete history helps patients and healthcare providers appreciate both the remarkable scientific achievement and the artificial barriers to access. This knowledge empowers advocacy for policy changes, informed treatment decisions, and recognition that current insulin pricing represents a departure from historical norms rather than an inevitable consequence of scientific progress.
How to Apply These Findings in Daily Life
- Learn about different insulin types and their historical development
- Understand that current high prices are not inevitable or justified by research costs
- Advocate for policies that restore insulin’s accessibility
- Explore older insulin formulations that may be more affordable
- Support research into generic insulin development
- Connect with patient advocacy organizations working on insulin access
- Discuss insulin history and pricing with healthcare providers
Limitations To Keep In Mind
This is a short narrative review, and it ends in 2012, before newer ultra-long-acting insulins and lower-cost biosimilar insulins. It tells the discovery mainly as a Toronto story, while other researchers, such as Nicolae Paulescu, also produced pancreatic extracts. Additionally, the focus on insulin development may not fully capture the broader context of diabetes care evolution, including glucose monitoring, dietary management, and other therapeutic advances.
Related Studies
- The Internal Secretion of the Pancreas
- Nicolae Paulescu’s Original Contributions
- Insulin in America: A Right or a Privilege?
- 100 Years of Insulin: Why Is It So Expensive?
- Episode 24: The Discovery of Insulin
FAQs
What’s the difference between old and new insulin types?
Early insulin was extracted from animal pancreases and had variable purity and duration. Modern insulin is genetically engineered human insulin or modified analogs with precise action profiles. While newer insulins offer convenience advantages, older formulations remain effective for diabetes management.
Why did insulin prices start rising so dramatically after 2000?
The shift from simple human insulin to patented analog formulations allowed manufacturers to maintain exclusivity and prevent generic competition. This coincided with healthcare system changes that shifted costs to patients through higher deductibles and copays.
Are there still affordable insulin options available?
Yes, older human insulin formulations like NPH and regular insulin remain available at lower costs, though they require more careful timing and monitoring. Some states have also implemented insulin price caps and emergency access programs.
Conclusion
Insulin’s history demonstrates both the power of scientific collaboration and the dangers of treating life-saving medications as luxury commodities. The journey from Banting’s 1921 experiments to modern precision therapy deserves celebration, and the accessibility the original discoverers intended deserves to be restored. The next chapter of insulin’s history should focus on ensuring that this life-saving therapy reaches everyone who needs it.
